about
sameAs
PEGylated Adenoviruses: From Mice to MonkeysSite-Specific PEGylation of Therapeutic ProteinsPolymer-drug conjugates: origins, progress to date and future directionsHow to manage asparaginase hypersensitivity in acute lymphoblastic leukemiaSmall Molecule Activation of PKM2 in Cancer Cells Induces Serine AuxotrophyAdvances in PEGylation of important biotech molecules: delivery aspectsRefolding and purification of recombinant L-asparaginase from inclusion bodies of E. coli into active tetrameric protein.Emerging PEGylated drugs.PEGylation of bacterial cocaine esterase for protection against protease digestion and immunogenicityEnabling individualized therapy through nanotechnologyMacromolecular therapeuticsAsparagine synthetase chemotherapy.An inhibitor of human asparagine synthetase suppresses proliferation of an L-asparaginase-resistant leukemia cell line.Polymer-drug conjugates: recent development in clinical oncologySpecies differences in the pharmacology and toxicology of PEGylated helper-dependent adenovirusNoninvasive detection of passively targeted poly(ethylene glycol) nanocarriers in tumors.Polymeric conjugates for drug deliveryEmerging drugs for adult acute lymphoblastic leukaemia.Influence of molecular size on the retention of polymeric nanocarrier diagnostic agents in breast ducts.Polymer conjugates as anticancer nanomedicines.Acute reactions to chemotherapy agents.Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignanciesPEGylation of bacteriophages increases blood circulation time and reduces T-helper type 1 immune responseL-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL).L-Asparaginase Isolated from Phaseolus vulgaris Seeds Exhibited Potent Anti-Acute Lymphoblastic Leukemia Effects In-Vitro and Low Immunogenic Properties In-Vivo.Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study.A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety.Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application.Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSF.Adult acute lymphoblastic leukemia: concepts and strategies.Peg-asparaginase for acute lymphoblastic leukemia.Product development issues for PEGylated proteins.Nanoparticulate drug delivery systems for cancer chemotherapy.Multifunctional Poly(ethylene glycol)s.Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.Targeting methionine auxotrophy in cancer: discovery & exploration.Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases.Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults.Improving the stability and activity of oral therapeutic enzymes-recent advances and perspectives.Polymeric micelles with stimuli-triggering systems for advanced cancer drug targeting.
P2860
Q24635276-F3473C53-C207-44B7-92FD-1CA30FA0F160Q26777819-17DD2585-B4A8-4B2D-BD8E-B65C9CA06279Q27002505-43ECFB96-414B-4792-931F-74F6ADD64D3FQ27026952-63EB0E3B-C8A1-4ED8-B042-671D5AE794A1Q27673508-1449EBED-D462-4618-A811-CDC19C058826Q28277255-471FACF7-5EDE-4CAA-8C89-B2D9A8E28061Q30367759-330D95D3-F553-415B-B280-07297FE653C3Q33447691-D633D404-35B8-4E62-8636-B15691E687C2Q33665491-1B9F7C40-C2FF-4264-87DB-73856DF6D901Q33917755-311E5CCB-3D81-4826-B17E-E648B95DC070Q34079574-B747AD32-DFA6-4F75-8C3A-260E353AEEF5Q34535185-3C39877C-A295-4489-8FB9-72BADCCBC9C8Q34653242-6388028B-3E00-4B79-BEDF-0CA41A20303CQ34656003-30BD706B-446E-420A-B845-7C8EAE26955CQ34975214-3AD177E6-CB7E-43BD-9A2E-3E3042AE8790Q35671286-23404012-D406-4954-A828-EC91676FF449Q36029175-9885EB12-09FF-44EA-ADD4-B7D4E3844CB0Q36219661-9CBE3CF5-D404-48A3-8A11-167EA526B36CQ36235198-25791A19-3BDF-4607-9F4B-7D8F9942E968Q36561667-385E3D17-3B82-45E8-A7BA-A2B07471B379Q36615308-718B65B2-2D3F-4588-AD87-81CA25BB524DQ37165245-792E5333-8D4A-4788-987A-DBA5D8E066B5Q37274884-BCE13651-282C-40FA-A5EC-D32D1D6FE7E5Q37371369-7C12E3DE-E99D-4297-B40F-C08396920753Q37379199-4E51F5F0-4D4F-44D8-9651-8D1448B5BBA0Q37522294-C1F58A0F-A5C7-408E-8C33-4FAD7D6F3761Q37562460-1C15F9D7-08DA-4A65-88F2-FE822934CC72Q37612333-0701A00D-A23A-4CB9-80BE-765C94F6518EQ37679949-55B24833-C047-4FEE-97C2-0B07CAF8A3C8Q37681450-AD15F264-549A-4DCB-A345-52D6D14C918FQ37719558-67A33F7A-8B81-4DEC-A913-7E6123BCF6F0Q37790702-3BE85B01-83A6-4B1B-AE87-C7D59CC31AF0Q37799616-F61A4262-7ADA-4E86-B600-49C1979175B9Q37900556-C5417756-B35F-474B-A908-FFDEC0D17788Q37914185-C0ABF2E8-119A-4678-982A-CC5534636BBCQ37968630-011318C6-772E-4F88-8584-24028F16C580Q38056128-35CBB315-67E0-4AEB-B8B2-2F5C94BC32F4Q38079075-469993D7-BAF9-4130-B8E1-465D94B14BDCQ38159436-56E801A2-7A24-401F-8258-6B8AE0AE49D3Q38228139-D6C73DE5-82F9-451D-ABFF-E186953AFACC
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Pegaspargase: a review of clinical studies
@ast
Pegaspargase: a review of clinical studies
@en
Pegaspargase: a review of clinical studies
@nl
type
label
Pegaspargase: a review of clinical studies
@ast
Pegaspargase: a review of clinical studies
@en
Pegaspargase: a review of clinical studies
@nl
prefLabel
Pegaspargase: a review of clinical studies
@ast
Pegaspargase: a review of clinical studies
@en
Pegaspargase: a review of clinical studies
@nl
P3181
P1476
Pegaspargase: a review of clinical studies
@en
P2093
Michael L Graham
P304
P3181
P356
10.1016/S0169-409X(03)00110-8
P407
P577
2003-09-26T00:00:00Z